New updates on allergy and anaphylaxis
Reading File
Searching PubMed
allergy anaphylaxis management guidelines
Searching the Web
allergy anaphylaxis new updates 2025 2026 guidelines treatment
Reading Article
Reading Article
Reading Article
Reading Article
Reading Web Page
anaphylaxis allergy new updates 2025 2026
Finding Sources
Reading File
Searching PubMed
epinephrine nasal spray neffy anaphylaxis
Searching PubMed
omalizumab food allergy immunotherapy anaphylaxis
I now have comprehensive information to provide a thorough, well-organized update. Here is the full response:
Updates in Allergy and Anaphylaxis (2024-2026)
Below is a synthesis of the most important recent developments across guidelines, drug delivery, diagnostics, fatal risk predictors, food allergy management, and immunotherapy.
1. Revised Anaphylaxis Management Guidelines
Swedish SFFA Guidelines (Autumn 2024) - Key Paradigm Shifts
The updated Swedish Association for Allergology (SFFA) guidelines introduced several evidence-based changes that are being echoed globally ([PMID: 41408837]):
- Corticosteroids are no longer routinely recommended in acute anaphylaxis - the historical practice of adding dexamethasone or hydrocortisone is now explicitly discouraged.
- Severity grading has been abandoned - replaced by NIAID/FAAN diagnostic criteria for cleaner decision-making.
- Antihistamines are post-stabilization only - they have no role in acute phase management.
- Adrenaline remains the only evidence-based acute intervention and must be given immediately intramuscularly without delay, regardless of perceived severity.
- Serum tryptase measurement, documentation, and observation are emphasized for continued care and long-term management.
2023 Joint Task Force Practice Parameter (US)
Key pearls highlighted in 2025 ([PMID: 39254667]):
- Reinforces epinephrine first-line without hesitation
- Updated observation period guidance
- Clearer direction on biphasic anaphylaxis monitoring
2. New Epinephrine Delivery: Neffy (Intranasal Epinephrine)
One of the most significant practical developments is the FDA-approved epinephrine nasal spray (neffy), approved in late 2025.
- Needle-free delivery - addresses a major barrier to self-administration (needle phobia, hesitancy)
- Approved based on pharmacokinetic data showing non-inferiority to IM injection
- A 2026 crossover study of 43 adults confirmed: second dose in the same nostril (per manufacturer instructions) gives better sustained epinephrine exposure than alternating nostrils or IM injection, even in patients with inflamed nasal passages (J Allergy Clin Immunol Pract 2026; 14:837)
- A Phase 3 trial in Japan confirmed neffy improves symptoms during oral food challenge (PMID: 40639499)
- Pediatric PK/PD data now available ([PMID: 40120808])
- Real-world anaphylaxis use data is still limited but reassuring
- Does NOT replace auto-injectors in all settings - IM epinephrine remains the gold standard for severe anaphylaxis
3. Predictors of Fatal Anaphylaxis - New Systematic Review (2026)
A major systematic review across 28 studies from 20 countries ([PMID: 41701644]) identified key predictors of fatality:
Triggers:
- Peanuts and cow's milk (in children <18)
- Antibiotics, contrast media, and neuromuscular blockers (perioperative, especially in adults ≥65)
- Insect stings (venom)
High-risk comorbidities:
- Asthma
- Cardiovascular disease (heart failure, ischemic disease, hypertension)
- Age ≥65 years
- Multiple comorbidities together greatly amplify risk
Critical intervention failure:
- Delayed epinephrine (>30 min after symptom onset) or failure to give it in the prehospital setting was consistently associated with fatal outcomes - this is the most modifiable risk factor.
4. Organ Failure Pattern in Fatal Anaphylaxis (2026 Systematic Review)
A BMJ Open systematic review of 896 deaths ([PMID: 41802785]) gives important mechanistic clarity:
| Allergen Trigger | Primary Organ Failure |
|---|---|
| Food | Respiratory (95% - mainly bronchospasm) |
| Drug | Respiratory in 65% of cases |
| Venom (insect sting) | Cardiovascular in 65% of cases |
Implication: Guidelines should place greater emphasis on respiratory management (bronchospasm) in food and drug-triggered anaphylaxis, and on cardiovascular support in venom-triggered cases. Current guidelines may be under-emphasizing bronchospasm. Prospective registries are needed.
5. EAACI Food Allergy Guidelines (2025)
The European Academy of Allergy and Clinical Immunology published updated GRADE-based guidelines ([PMID: 39473345]):
Standard care (all patients):
- Allergen avoidance + specialist dietitian support
- Written emergency action plan
- Epinephrine auto-injector prescription with education
- Psychological support for patients with significant anxiety
Immunomodulatory options (new emphasis):
- Omalizumab (anti-IgE): Suggested for IgE-mediated food allergy in children from age 1 and adults
- Oral immunotherapy (OIT): Recommended for peanut allergy in children and adolescents; suggested for milk and egg (generally after age 4)
- Sublingual and epicutaneous immunotherapy: Suggested for peanut allergy but not yet widely available at point of care
6. Drug Hypersensitivity - New EAACI Position Paper (April 2026)
New EAACI position paper on hypersensitivity to drug excipients (inactive ingredients like dyes, preservatives, surfactants) - an under-recognized cause of allergic reactions and anaphylaxis. Guidance now formalizes workup and counseling for patients reacting to non-active drug components (UpToDate, April 2026; Garvey et al., Allergy 2026).
7. Remimazolam-Induced Anaphylaxis
A systematic review of 11 cases ([PMID: 38929588]) highlights remimazolam, a newer benzodiazepine used in procedural sedation, as an emerging cause of anaphylaxis with cardiovascular collapse. Clinicians using remimazolam should be prepared for this rare but severe reaction.
8. Alpha-Gal Syndrome Update
Still gaining recognition: sensitization to alpha-gal protein following lone star tick bites causes delayed IgE-mediated anaphylaxis to mammalian meat and some drugs. A 2026 study noted higher rates of adverse drug reactions to crotalidae (snake) antivenom in alpha-gal endemic areas (Filip et al., Ann Emerg Med 2026).
Summary of Key Practice Changes
| Change | Old Practice | New Evidence/Recommendation |
|---|---|---|
| Corticosteroids in acute anaphylaxis | Routinely given | No longer recommended |
| Severity grading | Used to guide treatment | Replaced by NIAID/FAAN criteria |
| Antihistamines | Given acutely | Post-stabilization only |
| Epinephrine delivery | Auto-injector only | Intranasal spray (neffy) now available |
| Food allergy immunotherapy | Mainly avoidance | Omalizumab + OIT now guideline-recommended |
| Fatal trigger organ failure | Generic approach | Tailored to trigger (respiratory vs. cardiovascular) |
Key PubMed References:
- Fatal anaphylaxis predictors: PMID: 41701644
- Organ failure in fatal anaphylaxis: PMID: 41802785
- EAACI food allergy guidelines: PMID: 39473345
- Updated Swedish anaphylaxis guidelines: PMID: 41408837
- Neffy development review: PMID: 38931932
- Neffy Phase 3 trial: PMID: 40639499
Textbook background: Rosen's Emergency Medicine 9e; Goldman-Cecil Medicine
Create a clinical protocol poster on the new anaphylaxis management steps
Generating Image
Here is your clinical protocol poster covering all 6 management steps based on the updated 2024-2026 guidelines. Key highlights built into the poster:
- Step 1 uses the current NIAID/FAAN diagnostic criteria (replacing severity grading)
- Step 2 emphasizes immediate epinephrine with no delay, and includes neffy (intranasal epinephrine) as the new needle-free option with the correct dosing instruction (second dose in the same nostril)
- Step 5 explicitly marks corticosteroids as no longer routinely recommended and repositions antihistamines as post-stabilization only
- Step 6 lists the key fatal risk factors from the 2026 systematic review (asthma, CVD, age ≥65, delayed epinephrine)
The footer warning reinforces the single most important message: epinephrine is the only acute-phase intervention that saves lives.
Make a presentation on fatal anaphylaxis predictors and high-risk patient management
Reading File
Reading File
Reading File
Reading File
Running Command
Writing File
Running Command
Running Command
Your presentation is ready - 333 KB, 10 slides:
Fatal Anaphylaxis Predictors Management
Presentation · PPTX
Here is what's in each slide:
| Slide | Title | Design |
|---|---|---|
| 1 | Title Slide | Dark navy with crimson accents, epidemiology stat callouts |
| 2 | Epidemiology & Background | Trigger doughnut chart + key fact bullets |
| 3 | Predictors of Fatal Anaphylaxis | 3-column cards: Triggers / Comorbidities / Modifiable factors |
| 4 | Organ Failure Patterns by Trigger | Stacked bar chart (Respiratory vs Cardiovascular by allergen) + insight cards |
| 5 | High-Risk Patient Identification | 6 risk cards with color-coded severity tiers |
| 6 | Immediate Management | Step-by-step timeline with connector, color-coded by urgency |
| 7 | High-Risk Specific Adjustments | 3 columns: Asthma / CVD+Elderly / Mastocytosis |
| 8 | Discharge & Long-term Management | Observation table + discharge checklist + immunotherapy (OIT, omalizumab) |
| 9 | Key Clinical Messages | 5 numbered dark take-home banners |
| 10 | References | All 10 sources with PMID tags |
Evidence base: Chowdhury et al. (PMID: 41701644), McKenzie et al. (PMID: 41802785), EAACI 2025 (PMID: 39473345), SFFA Guidelines 2024, Rosen's Emergency Medicine, Goldman-Cecil Medicine.
Search for clinical images of anaphylaxis and airway management
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Loading Image
Loading Image
Loading Image
Loading Image
Loading Image
Reading File
Finding Sources
Reading File
Reading File
Reading File
Reading File
I have a very good collection of images. Let me now present everything I found with full context and clinical annotations:
Clinical Images: Anaphylaxis & Airway Management
All images are sourced from authoritative medical textbooks in the library.
SECTION 1 — ANAPHYLAXIS: SKIN & MUCOCUTANEOUS MANIFESTATIONS
Image 1 — Angioedema (Urticarial Drug Eruption)
Source: Andrews' Diseases of the Skin, Clinical Dermatology
Fig. 6.29 — Angioedema. (Courtesy Steven Binnick, MD.) This image demonstrates severe cutaneous involvement showing profound erythema and cyanotic discoloration of the toes with inflammatory erythema at the base of the foot - consistent with severe vasodilatory and vascular permeability changes seen in anaphylaxis. The dark discoloration of the toes reflects vascular congestion/stasis from massive histamine-mediated vasodilation.
Clinical context: Urticarial drug eruptions are the second most common cutaneous adverse drug reaction. Urticaria around the face or extremities may signal impending systemic anaphylaxis with bronchospasm, laryngospasm, or hypotension. - Andrews' Diseases of the Skin, p. 144
SECTION 2 — AIRWAY MANAGEMENT ALGORITHMS
Airway compromise is the primary cause of death in 95% of food-triggered and 65% of drug-triggered fatal anaphylaxis. The following are clinical airway management algorithms from major anesthesia textbooks:
Image 2 — ASA Difficult Airway Algorithm
Source: Morgan & Mikhail's Clinical Anesthesiology, 7e (Fig. 19-29)
Fig. 19-29 — ASA Difficult Airway Algorithm. Shows the complete decision tree from initial assessment through awake intubation vs. post-induction pathways, through non-emergency and emergency branches, ending at emergency invasive airway access when CICO (can't intubate, can't oxygenate) is declared. - Morgan & Mikhail's Clinical Anesthesiology, 7e, p. 608
Image 3 — DAS 2015 Difficult Airway Guidelines: Overview
Source: Morgan & Mikhail's Clinical Anesthesiology, 7e (Fig. 19-30A)
Fig. 19-30A — Difficult Airway Society (DAS) 2015 Guidelines: Overview. Four-plan stepwise approach:
- Plan A - Facemask ventilation + tracheal intubation (laryngoscopy)
- Plan B - Maintaining oxygenation: SAD (supraglottic airway device) insertion
- Plan C - Final attempt at facemask ventilation
- Plan D - Emergency front-of-neck access (cricothyroidotomy) The "STOP AND THINK" box appears after Plan B success - critical decision point.
Image 4 — DAS 2015: Detailed Stepwise Management
Source: Morgan & Mikhail's Clinical Anesthesiology, 7e (Fig. 19-30B)
Fig. 19-30B — DAS 2015 Detailed Protocol. Specifies maximum intubation attempt limits (3+1), external laryngeal manipulation, bougie use, and step-by-step SAD insertion criteria. Emphasizes calling for help early and declaring CICO before Plan D. - Morgan & Mikhail's Clinical Anesthesiology, 7e, p. 610
Image 5 — CICO Emergency: Failed Intubation, Failed Oxygenation
Source: Morgan & Mikhail's Clinical Anesthesiology, 7e
CICO Rescue — Plan D: Emergency Front-of-Neck Access. The critical final pathway when all intubation and ventilation attempts fail. Steps: Call for help → Declare CICO → Continue 100% O₂ via upper airway → Extend neck → Scalpel cricothyroidotomy (No. 10 blade + bougie + 6mm cuffed tube). This scenario is most relevant in anaphylactic angioedema of the airway - where laryngeal/supraglottic edema makes laryngoscopy impossible. - Morgan & Mikhail's Clinical Anesthesiology, 7e, p. 611
Clinical Relevance to Anaphylaxis Airway Management
| Scenario | Preferred Approach |
|---|---|
| Mild stridor, early angioedema | IM epinephrine + O₂ + upright positioning |
| Worsening angioedema, partial obstruction | Early RSI with video laryngoscopy + surgeon standby |
| Severe laryngeal edema, failed laryngoscopy | DAS Plan B (SAD) or direct Plan D (cricothyroidotomy) |
| CICO in full anaphylactic arrest | Scalpel cricothyroidotomy per DAS 2015 |
Key teaching point from the 2026 BMJ Open systematic review (PMID: 41802785): Respiratory failure (primarily bronchospasm and upper airway obstruction) is the dominant cause of death in food and drug-triggered anaphylaxis (95% and 65% respectively). Early airway management is as important as epinephrine in these cases.
Sources: Morgan & Mikhail's Clinical Anesthesiology 7e | Andrews' Diseases of the Skin | Dermatology 5e | Rosen's Emergency Medicine 10e
Find latest research on predictive biomarkers for anaphylaxis severity
Searching PubMed
biomarkers anaphylaxis severity prediction tryptase
Searching PubMed
anaphylaxis serum biomarkers platelet activating factor histamine
Finding Sources
Searching the Web
anaphylaxis predictive biomarkers severity 2025 2026 tryptase PAF research
Reading File
Searching PubMed
anaphylaxis biomarkers diagnosis systematic review meta-analysis
Searching PubMed
mast cell activation tryptase basophil anaphylaxis novel markers
Reading Web Page
biomarkers anaphylaxis severity prediction tryptase PAF omics
Reading Article
Reading Article
Reading Article
Reading Article
Reading File
Searching PubMed
anaphylaxis multi-omics proteomics metabolomics severity biomarkers
Reading Article
Reading Article
Reading Article
Finding Sources
I now have a comprehensive, evidence-rich picture. Here is the full synthesis:
Predictive Biomarkers for Anaphylaxis Severity: Latest Research (2023-2026)
Overview
The field is moving from single-biomarker approaches (tryptase alone) toward multi-biomarker panels and multi-omics integration. Five main biomarker categories are currently studied, with several emerging candidates gaining traction.
1. Tryptase — The Reference Biomarker
Tryptase remains the most clinically used and best-validated biomarker. Recent systematic review data (2025-2026) sharpen its interpretation significantly.
Diagnostic Performance (Meta-Analysis, 2025)
Khalaf et al., J Allergy Clin Immunol Pract 2025 - Systematic review + meta-analysis of 28 studies, 18,749 patients ([PMID: 40239922]):
- Pooled sensitivity: 49% | Pooled specificity: 82%
- Tryptase has high specificity but misses ~half of confirmed anaphylaxis cases (low sensitivity)
- Most reliable using the "Rule of Twos" (20%+2 rule) dynamic threshold strategy
The "20%+2" Rule (Harrison's 22e, 2025)
A tryptase level drawn during possible anaphylaxis that is 20% above the patient's baseline plus 2 ng/mL is diagnostic for acute mast cell activation.
- Tryptase peaks 60-90 min after onset; measurable up to 5 hours
- Normal range upper limit: 11.4 ng/mL (fixed) - but fixed thresholds underperform
- Dynamic thresholds (relative rise) outperform fixed cutoffs: sensitivity 77% vs 60%
Perioperative Setting (Meta-Analysis, 2026)
Petrișor et al., Diagnostics 2026 ([PMID: 41975726]):
- Fixed threshold optimal cutoff: 12.68 ng/mL → sensitivity 59.8%, specificity 95.2%
- Dynamic thresholds → sensitivity 77.2%, specificity 88.5%
- Conclusion: dynamic tryptase thresholds are clearly superior for perioperative hypersensitivity
Post-Mortem Tryptase for Forensic Diagnosis (Systematic Review, 2025)
Pilia et al., Legal Med 2025 - 20 studies, 1,033 individuals, 221 anaphylactic deaths ([PMID: 40987006]):
- Optimal clinical balance cutoff: 30.4 ng/mL → sensitivity 88.2%, specificity 87.0%
- Youden's J optimal cutoff: 74.2 ng/mL (maximizes sensitivity + specificity)
- Exclusion threshold: <12.0 ng/mL (negative likelihood ratio) rules out anaphylactic death
- Sensitivity stable across 30-60 ng/mL range; specificity increases with higher thresholds
Hereditary Alpha-Tryptasemia (HAT) - Critical Confounder
- ~4-6% of Caucasians carry extra TPSA1 gene copies (chromosome 16) → elevated baseline tryptase
- HAT modulates anaphylaxis severity and predicts severe reactions
- KIT p.D816V mutation - associated with clonal mast cell disorders and severe anaphylaxis predisposition
- Both require specialized testing, limiting availability to referral centers
2. Platelet-Activating Factor (PAF) — High Severity Signal, Low Practicality
PAF is the most promising severity-specific biomarker but has major practical limitations.
Key findings (from multi-omics review, Svetina et al., Clin Rev Allergy Immunol 2025 [PMID: 40588688]):
- PAF levels correlate directly with reaction severity in both adults and children (Vadas et al.)
- PAF may identify more anaphylaxis cases than tryptase or histamine alone - potentially a superior diagnostic marker
- PAF-acetylhydrolase (PAF-AH) - the degrading enzyme - decreases during anaphylaxis and predicts severity; low PAF-AH = high PAF = worse reaction
Why not in routine use:
- Rapidly degraded by PAF-AH in vivo → inherently unstable sample
- Difficult to measure accurately in routine clinical labs
- No validated point-of-care assay
3. Histamine — Early Window, Fading Fast
- Pooled sensitivity: 76%, specificity: 69% (Khalaf meta-analysis 2025)
- Better sensitivity than tryptase but window is very narrow: measurable <1 hour from onset
- Useful if drawn very early; practically limited in most clinical settings
- In perioperative setting: fixed cutoffs → sensitivity 78%, specificity 85% (Petrișor 2026)
- Urinary N-methylhistamine (histamine metabolite) has a longer window but still limited data
4. Urinary Prostaglandin D2 (PGD2)
- PGD2 and its metabolites (9α,11β-PGF2) are elevated shortly after anaphylaxis onset
- Longer half-life than histamine in urine
- Data still limited - insufficient studies for pooled meta-analysis (Khalaf 2025)
- Listed by Harrison's 22e as a mast cell-derived mediator useful in acute biomarker panels
- Primarily useful for confirming mast cell involvement when tryptase is normal
5. Serum Ferritin — Novel IgG-Mediated Anaphylaxis Marker
A newly identified pathway biomarker ([PMID: 40447197], J Allergy Clin Immunol 2025):
- In IgG-mediated (non-IgE) anaphylaxis, serum ferritin rises sharply within 30 min and persists 24-36 hours - far longer than tryptase
- This does NOT occur in IgE-mediated anaphylaxis
- Mechanism: requires neutrophils, mast cells, oxidative stress, and histamine
- Clinical implication: ferritin elevation could help identify and differentiate IgG-mediated anaphylaxis - a pathway often missed by standard tryptase testing
6. Emerging & Novel Biomarkers
From the Hymenoptera venom review (Wilińska et al., Front Allergy 2026 [PMID: 42109509]) and multi-omics review (PMID: 40588688):
| Biomarker | Category | Potential Role |
|---|---|---|
| Osteopontin | Protein | Mast cell activation marker; novel severity predictor |
| KIT p.D816V mutation | Genomics | Predicts clonal mast cell disorder; severe reaction risk |
| PGD2 metabolites | Metabolomics | Confirm mast cell involvement when tryptase normal |
| Regulatory T-cell signatures | Transcriptomics | Immune modulation of reaction severity |
| Basophil activation test (BAT) | Functional | In vitro IgE sensitization confirmation; bypasses skin testing risk |
| Component-resolved IgE (e.g., Api m 1) | Serology | Better than whole-venom IgE for severity prediction in bee allergy |
| IL-6 elevation | Cytokine | Cytokine release reaction (CRR) marker; not IgE-mediated |
| Complement activation fragments | Proteomics | Contact system activation in severe mast-cell reactions |
7. Multi-Omics Integration — Where the Field is Heading
Svetina, Kunej, Korošec, Rijavec, Clin Rev Allergy Immunol 2025 ([PMID: 40588688]) - review of 107 studies across 5 omics layers:
| Omics Layer | Studies Reviewed | Key Findings |
|---|---|---|
| Genomics | 43 | TPSA1 duplications (HAT), FcεRI polymorphisms, MRGPRX2 variants |
| Transcriptomics | 20 | Mast cell activation gene signatures; IL-4/IL-13 pathway upregulation |
| Proteomics | 26 | PAF-AH, tryptase isoforms, complement fragments, osteopontin |
| Metabolomics | 14 | Eicosanoids (PGD2, leukotrienes), PAF, ceramides |
| Epigenomics | 2 | DNA methylation patterns in mast cell priming |
Major gap identified: No large-scale, integrative multi-omics study in human anaphylaxis exists yet. Current knowledge is fragmented across single-layer studies.
8. Biomarkers in Bee Venom Allergy — Best Risk Stratification Model
Na et al., J Pharmacopuncture 2026 ([PMID: 41953549]) - 9 studies, >1,100 participants:
- Baseline serum tryptase (BST) = strongest predictor of severe systemic sting reactions (5/9 studies)
- Whole-venom specific IgE = poor severity predictor
- Component-resolved IgE (Api m 1) = potential value in beekeepers subgroup
- IgG/IgG4 baseline = not predictive; increased IgG4 during immunotherapy = protection
Clinical Summary — What to Measure and When
| Biomarker | When to Draw | Interpretation | Availability |
|---|---|---|---|
| Serum tryptase | 1-2h after onset + 24h baseline | >20%+2 above baseline = diagnostic | Routine |
| Histamine | Within 30-60 min of onset | >10 nmol/L supportive | Routine (narrow window) |
| Urine PGD2 metabolite | 0-4h after onset | Mast cell confirmation | Specialist |
| Baseline tryptase | When stable (weeks later) | >7.5 ng/mL: consider HAT/mastocytosis | Routine |
| Post-mortem tryptase | At autopsy | >30.4 ng/mL highly diagnostic | Forensic |
| PAF / PAF-AH | At onset | Severity prediction; low PAF-AH = severe | Research only |
| Serum ferritin | Within 30 min | Elevation = IgG pathway anaphylaxis | Novel/research |
| BAT | Outpatient workup | IgE sensitization confirmation | Specialist |
Key PubMed References:
- Khalaf et al. — Biomarker diagnostic utility meta-analysis: PMID: 40239922
- Pilia et al. — Post-mortem tryptase systematic review: PMID: 40987006
- Petrișor et al. — Perioperative biomarkers meta-analysis: PMID: 41975726
- Khodoun & Finkelman — Ferritin in IgG anaphylaxis: PMID: 40447197
- Svetina et al. — Multi-omics review (⚠ erratum published): PMID: 40588688
- Wilińska et al. — Venom allergy diagnostics: PMID: 42109509
- Na et al. — IgE/tryptase in bee venom: PMID: 41953549
Textbook sources: Harrison's Principles of Internal Medicine 22e | Cellular and Molecular Immunology (Abbas) | Katzung's Pharmacology 16e
This is a shared conversation. Sign in to Orris to start your own chat.